10-Q: Trulieve Cannabis Corp. Reports Q2 2026 Results Amid Deconsolidation

Trulieve Cannabis Corp. filed its Q2 2026 Form 10-Q, detailing a significant net loss driven by a $403.3 million loss on deconsolidation of Harvest, alongside revenue declines and operational adjustments.

Summary

• Trulieve Cannabis Corp. reported a net loss of $406.1 million for the three months ended June 30, 2026, compared to a net loss of $16.1 million in the prior year period.
• The significant loss was largely due to a $403.3 million loss on the deconsolidation of Harvest Enterprises, LLC.
• Revenue for the quarter decreased by 10% to $271.0 million from $302.1 million in the prior year, impacted by the deconsolidation and pricing pressures.
• Gross profit also decreased by 11% to $162.3 million, with gross margin slightly declining to 59.9% from 60.6%.
• Selling, general, and administrative expenses increased slightly to $101.8 million, representing a higher percentage of revenue (37.6%) compared to the prior year (33.5%).
• The company ended the quarter with $325.4 million in cash and cash equivalents.
• Trulieve applied for DEA licenses following the federal rescheduling of medical marijuana to Schedule III, deeming its operations federally lawful pending review.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to a significant net loss and a substantial loss on deconsolidation, despite some operational improvements and a positive outlook on federal rescheduling.

Positives

• The company ended the quarter with a strong cash position of $325.4 million.
• Revenue from management services provided under the MSA with Harvest contributed positively.
• The federal rescheduling of medical marijuana to Schedule III is expected to legitimize operations.
• Trulieve applied for DEA licenses, moving towards federal legality for its medical operations.
• The company reported compliance with all operating and financial covenants in its long-term borrowing agreements.
• A share repurchase program of up to $50.0 million was authorized in June 2026.

Negatives

• A substantial net loss of $406.1 million was reported for the three months ended June 30, 2026.
• A significant loss of $403.3 million on the deconsolidation of Harvest Enterprises, LLC was recorded.
• Revenue decreased by 10% to $271.0 million for the quarter, impacted by deconsolidation and pricing pressures.
• Gross profit decreased by 11% to $162.3 million.
• Selling, general, and administrative expenses increased as a percentage of revenue.
• The company reported an equity in net loss of Harvest of $3.3 million for the quarter.
• The company is facing a significant IRS audit with proposed taxes, interest, and penalties totaling approximately $38.1 million, though the company disputes the penalties.

Risks

• The uncertainty regarding the regulation of cannabis in the U.S. remains a significant risk.
• Intense competition in the cannabis industry could materially affect the business.
• The company faces risks related to maintaining licenses and obtaining new ones.
• The fair value of the equity method investment in Harvest is potentially volatile and a significant reduction in its value could adversely affect the company's financial condition.
• The company is subject to higher risk of IRS audit due to its industry.
• Restricted access to banking and other financial services for cannabis businesses poses operational challenges.
• The company may not be able to grow its product offerings and dispensary services effectively.
• The company faces risks related to product liability claims and potential product recalls.

Future Outlook

The company's outlook is influenced by the ongoing federal rescheduling of cannabis, which is expected to provide a more favorable regulatory environment. Trulieve is actively pursuing DEA licenses to solidify the federal legality of its medical operations. The company believes its current cash balance is sufficient for at least the next 12 months, with potential for further funding through operations or debt/equity financings.

Management Comments

• The Deconsolidation Transaction impacts the comparability of the Company's results of operations between periods.
• Gross margin will continue to fluctuate quarter to quarter depending on product and market mix, inventory sell through, promotional activity and idle capacity costs.
• The Company believes its operations are in material compliance with all applicable federal, state and local laws, regulations, and licensing requirements in the states in which we operate.
• Management believes its tax position is supportable and that it has substantive legal arguments regarding the IRS audit.

Industry Context

StockSavvy.ai notes that Trulieve's Q2 2026 results are heavily influenced by the significant deconsolidation of Harvest, which masks underlying operational trends. The company's strategic focus on federal rescheduling and DEA licensing is a critical development for the entire U.S. cannabis industry, potentially paving the way for greater regulatory clarity and market access.

Comparison to Industry Standards

• Trulieve's revenue decline of 10% in Q2 2026, while impacted by the deconsolidation, reflects broader pricing pressures seen in mature cannabis markets.
• The company's gross margin of 59.9% remains robust, generally in line with or exceeding margins reported by other vertically integrated multi-state operators (MSOs) in the U.S. cannabis sector.
• The significant net loss, largely due to a non-cash accounting charge, is a stark reminder of the financial complexities and regulatory hurdles faced by cannabis companies, particularly those undergoing significant corporate restructurings.
• The company's proactive approach to federal rescheduling and DEA licensing aligns with industry-wide efforts to navigate evolving federal regulations.

Legal Proceedings

• In September 2025, the IRS issued Revenue Agent Reports proposing assessment of taxes, interest, and penalties for some of the Company's subsidiaries. Trulieve has submitted protests to dispute these liabilities. The company believes it is more likely than not to prevail, but the position does not yet meet ASC 740 recognition threshold for tax years prior to 2026. The proposed penalty amount is approximately $38.1 million, which is not included in the company's uncertain tax position liabilities, and the company believes these penalties are without merit.

Related Party Transactions

• The company rents an asset from an entity directly owned in part by the CEO and Chair of the Board. Expense was $0.1 million for the three and six months ended June 30, 2026.
• The company leases a cultivation facility and corporate office from an entity indirectly owned by the CEO, Chair of the Board, another Board member, and a former Board member. Related party lease liabilities were $405,000 as of June 30, 2026.
• Revenue recognized under the Management Services Agreement (MSA) with Harvest was approximately $1.7 million for the three and six months ended June 30, 2026. Management services receivables were $22.9 million as of June 30, 2026.

Stakeholder Impact

• Shareholders are impacted by the significant net loss and the substantial non-cash charge from the deconsolidation, which negatively affects the stock price.
• Employees may experience uncertainty due to the financial results and ongoing restructuring, though the company emphasizes operational compliance.
• Creditors and lenders are impacted by the company's financial performance, though the company remains in compliance with its debt covenants.
• Suppliers may face potential payment delays if the company's financial situation deteriorates, though no immediate concerns are indicated.

Next Steps

• Complete the domestication of the Company to the State of Delaware and continuance out of the Province of British Columbia.
• Continue to work with the DEA to complete site inspections for federal registration of medical operations.
• Ramp up production and retail capacity in Texas pending regulatory approval.
• Monitor and manage the ongoing IRS audit and dispute proposed penalties.
• Evaluate the performance of the equity method investment in Harvest.

Key Dates

Recommendation

While the company's long-term strategy, including federal rescheduling and DEA licensing, presents potential upside, the significant net loss, substantial deconsolidation charge, and ongoing IRS scrutiny create considerable near-term risk. The strong cash position and operational compliance are positives, but the magnitude of the recent loss warrants a cautious 'hold' stance until operational recovery and regulatory clarity become more evident.

Keywords

Trulieve Cannabis, Cannabis Operations, Form 10-Q, Financial Results, Deconsolidation, Harvest Enterprises, Medical Cannabis, SEC Filing